No profile data available.
Galectin Therapeutics Inc. (GALT) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Norcross, United States, with about 9 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$30.97 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $397.35 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.
Galectin Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$397.35 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Wave Life Sciences Ltd. (WVE), Sagimet Biosciences Inc. (SGMT), Monopar Therapeutics Inc. (MNPR), Enanta Pharmaceuticals, Inc. (ENTA).